Year Founded
2007
Ownership
Private
Employees
~7
Therapeutic Areas
Oncology
Stage
Phase 3
Modalities
Subunit vaccine

Polynoma General Information

Developing seviprotimut-L, a polyvalent shed antigens vaccine for adjuvant treatment of melanoma. Currently conducting MAVIS (Melanoma Antigen Vaccine Immunotherapy Study), a multicenter, double-blind, placebo-controlled Phase III trial.

Contact Information

Website
Primary Industry
[ "Biotech" ]
Corporate Office
San Diego, California
United States

Drug Pipeline

seviprotimut-L
Phase 3
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Polynoma's pipeline data

Book a demo

Key Partnerships

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Polynoma Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Polynoma's complete valuation and funding history, request access »